See more : McCormick & Company, Incorporated (0JZS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Pa Shun International Holdings Limited (0574.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pa Shun International Holdings Limited, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Kriti Nutrients Limited (KRITINUT.BO) Income Statement Analysis – Financial Results
- Skeena Resources Limited (SKE) Income Statement Analysis – Financial Results
- EASY HOLDINGS Co., Ltd. (035810.KQ) Income Statement Analysis – Financial Results
- 727 Communications, Inc. (SVNJ) Income Statement Analysis – Financial Results
- GSP Automotive Group Wenzhou Co.,Ltd. (605088.SS) Income Statement Analysis – Financial Results
Pa Shun International Holdings Limited (0574.HK)
About Pa Shun International Holdings Limited
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution activities in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Self-Operated Retail Pharmacies, and Pharmaceutical Manufacturing. The Pharmaceutical Distribution segment sells pharmaceutical products to wholesalers, franchise retail pharmacy chain stores, and hospitals and other medical institutions in rural areas. The Self-Operated Retail Pharmacies segment engages in the sale of pharmaceutical and healthcare products, cosmetic products, and daily necessities in self-operated retail pharmacies. The Pharmaceutical Manufacturing segment sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is based in San Po Kong, Hong Kong. Pa Shun International Holdings Limited is a subsidiary of Praise Treasure Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.43M | 71.78M | 86.43M | 474.84M | 845.45M | 821.14M | 869.89M | 860.57M | 867.96M | 847.19M | 794.35M | 712.11M |
| Cost of Revenue | 100.00M | 58.48M | 73.47M | 457.14M | 803.52M | 760.86M | 780.48M | 746.63M | 702.70M | 665.13M | 643.92M | 582.58M |
| Gross Profit | 29.43M | 13.30M | 12.96M | 17.70M | 41.93M | 60.29M | 89.42M | 113.95M | 165.27M | 182.07M | 150.43M | 129.54M |
| Gross Profit Ratio | 22.74% | 18.53% | 14.99% | 3.73% | 4.96% | 7.34% | 10.28% | 13.24% | 19.04% | 21.49% | 18.94% | 18.19% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 819.00K | 8.00M | 1.30M | 16.05M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 23.60M | 12.83M | 16.85M | 26.27M | 35.23M | 55.31M | 40.59M | 51.43M | 78.12M | 46.73M | 25.78M | 25.14M |
| Selling & Marketing | 7.25M | 6.05M | 8.49M | 8.09M | 10.98M | 15.14M | 14.17M | 14.08M | 25.57M | 36.47M | 35.99M | 33.38M |
| SG&A | 30.84M | 18.88M | 25.34M | 34.35M | 46.21M | 70.46M | 54.75M | 65.52M | 103.69M | 83.20M | 61.77M | 58.52M |
| Other Expenses | -1.41M | 62.00K | -518.00K | -512.00K | -512.00K | -24.68M | 12.41M | -8.17M | 465.00K | 1.32M | 1.42M | 965.00K |
| Operating Expenses | 29.43M | 18.37M | 24.82M | 33.84M | 45.69M | 69.95M | 54.11M | 52.75M | 83.80M | 65.56M | 48.84M | 49.53M |
| Cost & Expenses | 130.99M | 76.85M | 98.30M | 490.98M | 849.21M | 830.80M | 834.58M | 799.38M | 786.50M | 730.68M | 692.77M | 632.10M |
| Interest Income | 3.00K | 7.00K | 103.00K | 3.14M | 625.00K | 711.00K | 2.00M | 187.00K | 2.18M | 1.72M | 268.00K | 425.00K |
| Interest Expense | 12.93M | 10.54M | 14.95M | 11.52M | 11.86M | 15.36M | 14.96M | 1.77M | 2.72M | 4.82M | 4.11M | 2.87M |
| Depreciation & Amortization | 3.31M | 3.63M | 6.44M | 7.09M | 7.28M | 5.63M | 5.81M | 7.66M | 9.59M | 9.99M | 4.29M | 3.33M |
| EBITDA | 19.65M | -5.00M | -6.10M | 2.05M | -171.35M | -26.85M | 40.17M | 62.33M | 90.93M | 125.34M | 105.82M | 84.19M |
| EBITDA Ratio | 15.18% | -6.96% | -7.05% | 0.43% | 2.32% | -3.47% | 6.56% | 7.24% | 10.48% | 14.79% | 13.32% | 11.82% |
| Operating Income | -1.56M | -5.00M | -6.10M | -5.03M | 12.33M | -34.13M | 51.28M | 54.67M | 81.34M | 115.35M | 101.53M | 80.86M |
| Operating Income Ratio | -1.21% | -6.96% | -7.05% | -1.06% | 1.46% | -4.16% | 5.89% | 6.35% | 9.37% | 13.62% | 12.78% | 11.35% |
| Total Other Income/Expenses | 4.97M | -38.09M | -306.28M | -409.62M | -186.72M | -38.39M | -15.68M | -20.87M | 6.54M | -44.64M | -20.27M | -53.59M |
| Income Before Tax | 3.41M | -43.16M | -53.98M | -425.76M | -190.48M | -48.05M | 19.50M | 28.44M | 113.01M | 71.87M | 81.31M | 26.42M |
| Income Before Tax Ratio | 2.63% | -60.12% | -62.45% | -89.67% | -22.53% | -5.85% | 2.24% | 3.30% | 13.02% | 8.48% | 10.24% | 3.71% |
| Income Tax Expense | 1.06M | 220.00K | 408.00K | -6.57M | 2.92M | 15.36M | 9.33M | 20.77M | 28.12M | 25.74M | 18.24M | 17.11M |
| Net Income | 2.35M | -43.38M | -54.38M | -419.19M | -193.40M | -59.41M | 10.18M | 7.68M | 88.26M | 45.94M | 63.07M | 9.41M |
| Net Income Ratio | 1.82% | -60.43% | -62.92% | -88.28% | -22.88% | -7.23% | 1.17% | 0.89% | 10.17% | 5.42% | 7.94% | 1.32% |
| EPS | 0.00 | -0.03 | -0.04 | -0.28 | -0.13 | -0.05 | 0.01 | 0.01 | 0.11 | 0.09 | 0.09 | 0.01 |
| EPS Diluted | 0.00 | -0.03 | -0.04 | -0.28 | -0.13 | -0.05 | 0.01 | 0.01 | 0.06 | 0.09 | 0.08 | 0.01 |
| Weighted Avg Shares Out | 1.48B | 1.47B | 1.47B | 1.47B | 1.45B | 1.12B | 1.01B | 1.00B | 780.32M | 525.54M | 703.00M | 727.00M |
| Weighted Avg Shares Out (Dil) | 1.47B | 1.47B | 1.47B | 1.47B | 1.45B | 1.12B | 1.01B | 1.00B | 884.25M | 525.54M | 1.00B | 727.00M |
Source: https://incomestatements.info
Category: Stock Reports